<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02993627</url>
  </required_header>
  <id_info>
    <org_study_id>IR.SBMU.nnftri.Rec.1395.63</org_study_id>
    <nct_id>NCT02993627</nct_id>
  </id_info>
  <brief_title>Effects of Spirulina Supplementation on Overweight or Obese Adults</brief_title>
  <official_title>Effects of Spirulina Supplementation on Anthropometric Measurements, Lipid Profile, Appetite, Liver Enzymes, Inflammatory and Glycemic Markers on Overweight or Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double-blind Randomized Controlled Clinical Trial investigators are going to study
      the effects of Spirulina supplementation on anthropometric measurements, lipid profile,
      appetite, liver enzymes, inflammatory and glycemic markers in a sample of overweight or obese
      adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sample of 40 obese and overweight subjects will be recruited from Nutrition And Diet
      Therapy Clinic Of Shahid Beheshti Medical University.

      This study is a double-blind Randomized Controlled Clinical Trial, that subjects will be
      randomly allocated to spirulina or placebo group according to the Random permuted blocks
      within strata method based on BMI. Subjects will consume 2 g spirulina daily (4 tablets of
      500mg), whereas the control group are going to receive identical placebo tablets. Subjects
      are asked to maintain their usual physical activity level during the intervention period and
      also avoid taking any other supplements or medications without consulting the investigators.
      Intervention period is designed to be 12 weeks that has been determined sufficient to record
      changes of study parameters. At the beginning of the study and after 12 weeks of
      intervention, morning blood samples will be collected after 12 h of fasting. Anthropometric
      parameters will be also measured at the beginning, week 6 and after 12 weeks of intervention.
      Subjects will be followed through social network to ensure their compliance with the study.
      Furthermore, subjects in both spirulina and placebo groups received low calorie diet (-500 or
      -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat during the study period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body weight</measure>
    <time_frame>week 12</time_frame>
    <description>body weight with minimum of clothes and without shoes through a calibrated scale and with the precision of 100gr</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>week 12</time_frame>
    <description>calculation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>waist circumference</measure>
    <time_frame>week 12</time_frame>
    <description>measuring with an inflexible tapeline with the precision of 0.1cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hip circumference</measure>
    <time_frame>week 12</time_frame>
    <description>measuring with an inflexible tapeline with the precision of 0.1cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>waist/hip ratio</measure>
    <time_frame>week 12</time_frame>
    <description>calculation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>body fat mass</measure>
    <time_frame>week 12</time_frame>
    <description>bioempedance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>body fat free mass</measure>
    <time_frame>week 12</time_frame>
    <description>bioempedance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>apetite</measure>
    <time_frame>week 12</time_frame>
    <description>questionaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum triaylglycerol</measure>
    <time_frame>week 12</time_frame>
    <description>enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum total cholesterol</measure>
    <time_frame>week 12</time_frame>
    <description>enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>e serum HDL-C</measure>
    <time_frame>week 12</time_frame>
    <description>enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum LDL-C</measure>
    <time_frame>week 12</time_frame>
    <description>calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum LDL-C/HDL-C</measure>
    <time_frame>week 12</time_frame>
    <description>calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum fasting glucose</measure>
    <time_frame>week 12</time_frame>
    <description>enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum insulin</measure>
    <time_frame>week 12</time_frame>
    <description>enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>week 12</time_frame>
    <description>calculation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum hs-CRP</measure>
    <time_frame>week 12</time_frame>
    <description>eliza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum adiponectin</measure>
    <time_frame>week 12</time_frame>
    <description>eliza</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum SGOT</measure>
    <time_frame>week12</time_frame>
    <description>enzymatic method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum SGPT</measure>
    <time_frame>week 12</time_frame>
    <description>enzymatic method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Spirulina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily intake of spirulina tablets weight reduction diet therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily intake of placebo tablets weight reduction diet therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Spirulina</intervention_name>
    <description>2 g(4* 500 mg tablets) daily intake of Spirulina Platensis</description>
    <arm_group_label>Spirulina</arm_group_label>
    <other_name>Spiruvit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diet therapy</intervention_name>
    <description>low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat</description>
    <arm_group_label>Spirulina</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>weight reduction diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI&gt;25 kg/m2

          -  No history of medications for obesity, diabetes, dyslipidemia, inflammatory disease
             within 3 months before the study

          -  No history of vitamin or antioxidant supplementation within 3 months before the study

          -  Giving written informed consent for participation

        Exclusion Criteria:

          -  Having chronic kidney or hepatic disease except NAFLD

          -  Havig hypo or hyperthyroidism

          -  Having autoimmune and infectious disease

          -  weight reduction diet therapy within 6 month from the intervention

          -  Having more than 3kg weight change in recent 2 months

          -  Having recent surgery

          -  Taking anticoagulant drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atoosa Saidpour</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Nutrition and Dietetics, Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reyhaneh yousefi</last_name>
    <phone>00982122357484</phone>
    <email>yousefi.ryhn@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Nutrition and Diet Therapy Clinic of Shahid Beheshti University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <zip>1981619573</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyhaneh yousefi, MSc. student</last_name>
      <phone>0098191998669</phone>
      <email>yousefi.ryhn@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Atoosa Saidpour, PHD</last_name>
      <phone>00989123026088</phone>
      <email>atoosa.saidpour@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Azadeh Mottaghi, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Torres-Duran PV, Ferreira-Hermosillo A, Juarez-Oropeza MA. Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: a preliminary report. Lipids Health Dis. 2007 Nov 26;6:33.</citation>
    <PMID>18039384</PMID>
  </results_reference>
  <results_reference>
    <citation>Park HJ, Lee YJ, Ryu HK, Kim MH, Chung HW, Kim WY. A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans. Ann Nutr Metab. 2008;52(4):322-8. doi: 10.1159/000151486. Epub 2008 Aug 19.</citation>
    <PMID>18714150</PMID>
  </results_reference>
  <results_reference>
    <citation>Parikh P, Mani U, Iyer U. Role of Spirulina in the Control of Glycemia and Lipidemia in Type 2 Diabetes Mellitus. J Med Food. 2001 Winter;4(4):193-199.</citation>
    <PMID>12639401</PMID>
  </results_reference>
  <results_reference>
    <citation>Miczke A, Szulińska M, Hansdorfer-Korzon R, Kręgielska-Narożna M, Suliburska J, Walkowiak J, Bogdański P. Effects of spirulina consumption on body weight, blood pressure, and endothelial function in overweight hypertensive Caucasians: a double-blind, placebo-controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2016;20(1):150-6.</citation>
    <PMID>26813468</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazokopakis EE, Papadomanolaki MG, Fousteris AA, Kotsiris DA, Lampadakis IM, Ganotakis ES. The hepatoprotective and hypolipidemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study. Ann Gastroenterol. 2014;27(4):387-394.</citation>
    <PMID>25331487</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee EH, Park JE, Choi YJ, Huh KB, Kim WY. A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients. Nutr Res Pract. 2008 Winter;2(4):295-300. doi: 10.4162/nrp.2008.2.4.295. Epub 2008 Dec 31.</citation>
    <PMID>20016733</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Atoosa Saidpour</investigator_full_name>
    <investigator_title>Assistant Professor of Nutrition Science</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>BMI</keyword>
  <keyword>body weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>18039384</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-6-33/</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449559397&amp;partnerID=40&amp;md5=d8d36fa95497bf9e358abf2acbfa3923</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

